TTrialPathMatch Me to Trials
← Back to trials
RecruitingPulmonary Arterial HypertensionChronic Thromboembolic Pulmonary HypertensionPulmonary Hypertension

Pulmonary Hypertension Association Registry

Eligible age

0+ yrs

Accepts

All genders

Locations

28 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes. PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.

Sponsor: Pulmonary Hypertension Association, Inc.

You may qualify if…

  • All age groups
  • Written informed consent
  • Pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), or pediatric PH due to developmental lung disease
  • Within 6 months of first outpatient visit at a PH Care Center

You may not qualify if…

  • Diagnosis of WSPH Group 2 pulmonary hypertension
  • Diagnosis of WSPH Group 3 pulmonary hypertension, except PH due to developmental lung disease
  • Diagnosis of WSPH Group 5 pulmonary hypertension

Where it's recruiting

Arizona

Phoenix

California

Sacramento · San Francisco · Santa Barbara · Stanford

Colorado

Aurora

Connecticut

Farmington

Florida

Jacksonville

Georgia

Atlanta

Indiana

Indianapolis

Iowa

Iowa City

Kansas

Kansas City

Kentucky

Louisville

Louisiana

Jefferson · New Orleans

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT04071327 · last updated 2025-11-14

Pulmonary Hypertension Association Registry · TrialPath